PMID- 19922593
OWN - NLM
STAT- MEDLINE
DCOM- 20100219
LR  - 20141120
IS  - 1365-2559 (Electronic)
IS  - 0309-0167 (Linking)
VI  - 55
IP  - 6
DP  - 2009 Dec
TI  - Chromogenic in situ hybridization for Her-2/neu-oncogene in breast cancer: 
      comparison of a new dual-colour chromogenic in situ hybridization with 
      immunohistochemistry and fluorescence in situ hybridization.
PG  - 716-23
LID - 10.1111/j.1365-2559.2009.03427.x [doi]
AB  - AIMS: Her-2/neu testing is used as a marker for Herceptin therapy. The aim was to 
      investigate new dual-colour chromogenic in situ hybridization (CISH), in a large 
      number of breast carcinomas (n = 205) with DNA-specific dual-colour probes 
      (ZytoVision, Bremerhaven, Germany) and to compare the results with 
      immunohistochemistry (n = 205) and fluorescence in situ hybridization (FISH) (n = 
      129). METHODS AND RESULTS: Paraffin-embedded tissue of 205 patients was used. 
      After immunohistochemistry with a focus on immunohistochemically uncertain cases, 
      Her-2/neu amplification using dual-colour CISH (ZytoVision) was analysed. 
      Validation by FISH was performed. The results were: immunohistochemistry, 27.8% 
      with strong expression, 53.7% with uncertain overexpression and 18.5% with no 
      expression; FISH, 25.6% amplified and 74.4% negative; CISH, 35.6% amplified, 
      62.9% negative and 1.5% not evaluable. Comparison of immunohistochemistry with 
      CISH: CISH negative in 100% with immunohistochemistry 0/1+, amplified in 82.5% 
      with immunohistochemistry 3+; 5.9% contradictory results: 4.4% 
      immunohistochemistry 3+ and negative by CISH, 1.5% negative in 
      immunohistochemistry but amplified by CISH; FISH (129 cases), 8.5% contradictory 
      results to immunohistochemistry, 6.2% immunohistochemistry 3+ and negative by 
      FISH, 2.3% negative by immunohistochemistry and amplified by FISH; comparison of 
      CISH and FISH, 94.6% same results, 3.9% different ones, 1.6% CISH not analysable. 
      CONCLUSIONS: CISH, using dual-colour probes (ZytoVision) is as good as FISH for 
      Her-2/neu analysis. The few discrepant results are likely to be caused by 
      polysomy or tumour heterogeneity.
FAU - Mayr, Doris
AU  - Mayr D
AD  - Pathologisches Institut, Ludwig Maximilians Universitaet, Munchen, Germany. 
      doris.mayr@med.uni-muenchen.de
FAU - Heim, Sibylle
AU  - Heim S
FAU - Weyrauch, Kerstin
AU  - Weyrauch K
FAU - Zeindl-Eberhart, Evelyn
AU  - Zeindl-Eberhart E
FAU - Kunz, Anne
AU  - Kunz A
FAU - Engel, Jutta
AU  - Engel J
FAU - Kirchner, Thomas
AU  - Kirchner T
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Histopathology
JT  - Histopathology
JID - 7704136
RN  - 0 (Chromogenic Compounds)
RN  - 0 (RNA, Messenger)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Breast Neoplasms/genetics/*metabolism
MH  - Carcinoma/genetics/*metabolism
MH  - Chi-Square Distribution
MH  - Chromogenic Compounds
MH  - Female
MH  - Humans
MH  - Immunohistochemistry/*methods
MH  - In Situ Hybridization/*methods
MH  - Neoplasm Staging
MH  - RNA, Messenger/genetics/metabolism
MH  - Receptor, ErbB-2/genetics/*metabolism
EDAT- 2009/11/20 06:00
MHDA- 2010/02/20 06:00
CRDT- 2009/11/20 06:00
PHST- 2009/11/20 06:00 [entrez]
PHST- 2009/11/20 06:00 [pubmed]
PHST- 2010/02/20 06:00 [medline]
AID - HIS3427 [pii]
AID - 10.1111/j.1365-2559.2009.03427.x [doi]
PST - ppublish
SO  - Histopathology. 2009 Dec;55(6):716-23. doi: 10.1111/j.1365-2559.2009.03427.x.